The Management of Degenerative Complete Heart Block in the Time of Coronavirus
Published: 2022-09-03
Page: 273-279
Issue: 2022 - Volume 5 [Issue 1]
Jaouad Nguadi
Rhythmology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Meryem Bennani
Rhythmology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Youssef Lahmouz *
Clinical Cardiology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Zaynab Mouhib
Clinical Cardiology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Abdelilah Benelmekkki
Rhythmology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Najat Mouine
Clinical Cardiology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Hicham Bouzelmat
Rhythmology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Ali Chaib
Rhythmology Department, Cardiology Center, Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
Aatif Benyass
Mohammed V Military Instruction Hospital of Rabat, Mohammed V University, Morocco.
*Author to whom correspondence should be addressed.
Abstract
The use of chloroquine for SARS COV2 has been adopted by many countries around the world, including Morocco. The Chloroquine is known for its anti-arrhythmic and bradycardic effects and for its formal contraindication in cardiac conduction disorders, long QT and high-degree heart block, which makes the management of a complete heart block in a positive Covid a great dilemma for the rhythmologist. In this article, we describe the management of the association COVID 19-symptomatic high-degree heart block.
Keywords: Chloroquine, COVID-19, complete heart block